Overview

Ursodiol in Huntington's Disease

Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is processed by the body.
Phase:
Phase 1
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
Huntington Society of Canada
Huntington Study Group
Treatments:
Ursodeoxycholic Acid